Evaluation of the Prevalence of E. Coli O Serotypes in Paediatric Population With Recurrent Urinary Tract Infection

PENTA Foundation

Overview

This is a multicentre, observational, epidemiological study in which infants within the first 3 months of life with UTI and children aged ≥4 months with r-UTI will be recruited from nephrology /emergency departments and primary care in European countries

This is an international, multicenter, observational, cross-sectional epidemiological study. Study participants will undergo a screening phase and will be checked for study eligible and inclusion/exclusion criteria at study entry. No other visits will be conducted other than the first evaluation. The study will be conducted across up to 26 participating sites in Europe, including nephrology departments, paediatric emergency departments and primary care centers. Specifically, sites located more in Western and Eastern Europe will be involved in the study. In total, 600 participants with rUTI (UTI) will be included in this study, with approximately 200 participants for each age group (from 0 months to \< 3 years of age; from ≥ 3 to \< 12 years of age, from ≥ 12 to \< 18 years of age).

Study Type

OBSERVATIONAL

Conditions

Urinary Tract Infections

Eligibility

Sex: ALLMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age between 0 weeks and 17 years * Significant urine culture positive only for E. coli * For infants up to 3 months of age, a confirmed first UTI episode as identified by urine culture obtained by a sterile method (as described above) and positive for E. coli only (no other pathogens) * For children ≥4 months to \< 18 years a confirmed rUTI episode as identified by urine culture obtained by a sterile method (as described above) and positive for E. coli only (no other pathogens) * Collection of urine culture with a sterile method (suprapubic aspiration, bladder catheterization, clean voided urine) * Signed informed consent form (signed by participant's legally authorized representative for participants who have not attained the age of majority) * Signed Assent Form when appropriate, as determined by participant's age and individual site and country standards Exclusion Criteria: * Patients ≥18 years * Children ≥ 4 months of age with a first UTI episode * Absence of microbiological confirmation of UTI * UTI caused by bacteria other than E. coli or polymicrobial culture * Urine collected with a non-sterile method (urinary bag) * UTI episode within 30 days of the end of antibiotic treatment for the previous UTI episode * Second urine positive for E. coli during the same episode * Patients in the active phase of anticancer treatment

Outcomes

Primary Outcomes

To assess the serogroups of E. coli in the study cohort

The distribution \[N (%)\] of serotypes of E. coli in the study cohort will be evaluated separately for infants with UTI and children with r-UTI. Moreover, it will be evaluated separately for countries and age classification.

Time frame: January 2027

Secondary Outcomes

To assess the clinical profile, especially comorbidities, of children with UTI and rUTI

The comorbidity profiles of children with urinary tract infections (UTIs) and recurrent UTIs (rUTIs) will be characterize using descriptive statistics. This will involve presenting the frequency and percentages \[N (%) with Clopper-Pearson confidence interval\] for each comorbidity within each group.

Time frame: January 2027

• To assess the O-serotype distribution among drug-resistant E. coli, including multidrug resistant (MDR)

The number and percent (N \[%\]) of each O-serotype resistant to 0, 1, 2, 3, 4, and 5 antibiotic classes will be assessed. Antimicrobial susceptibility testing will use broth microdilution. Antibiotic panels will include antibiotics from 5 antimicrobial drug classes. Antibiotic resistance will be determined using minimal inhibitory concentration values and susceptibility criteria defined by either the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST).

Time frame: January 2027

To characterize drug resistance across O-serotypes of E. coli isolates that cause rUTIs in children

The resistance to representative antibiotics in the following 5 classes: aminoglycosides, cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, and sulfonamides will be reported. Based on these 5 classes (and representative antibiotics), the multidrug-resistant will be defined as isolates that were resistant to ≥3 of the 5 antibiotic classes listed. Resistance to last-resort antibiotics, carbapenems (doripenem, ertapenem, imipenem, and meropenem) and colistin will also be examined using Clinical and Laboratory Standards Institute breakpoints for minimum inhibitory concentration values.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.